Private Capital Advisors Inc. purchased a new stake in shares of SPDR S&P Biotech (NYSEARCA:XBI) during the 4th quarter, Holdings Channel reports. The fund purchased 14,834 shares of the exchange traded fund’s stock, valued at approximately $1,259,000.
Several other institutional investors also recently made changes to their positions in the stock. Covenant Asset Management LLC bought a new stake in shares of SPDR S&P Biotech during the 4th quarter valued at approximately $1,150,000. Train Babcock Advisors LLC bought a new stake in shares of SPDR S&P Biotech during the 4th quarter valued at approximately $815,000. Cumberland Advisors Inc. grew its holdings in shares of SPDR S&P Biotech by 916.1% during the 4th quarter. Cumberland Advisors Inc. now owns 41,660 shares of the exchange traded fund’s stock valued at $3,536,000 after purchasing an additional 37,560 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new stake in shares of SPDR S&P Biotech during the 3rd quarter valued at approximately $1,028,000. Finally, Hartline Investment Corp grew its holdings in shares of SPDR S&P Biotech by 1.2% during the 3rd quarter. Hartline Investment Corp now owns 92,282 shares of the exchange traded fund’s stock valued at $7,989,000 after purchasing an additional 1,070 shares during the last quarter.
Shares of SPDR S&P Biotech (NYSEARCA XBI) traded up $0.48 during trading on Friday, hitting $89.62. 6,230,673 shares of the company traded hands, compared to its average volume of 5,338,289. The company has a market cap of $4,710.00 and a price-to-earnings ratio of 4.92. SPDR S&P Biotech has a 12 month low of $61.14 and a 12 month high of $89.95.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://www.com-unik.info/2018/01/12/private-capital-advisors-inc-invests-1-26-million-in-spdr-sp-biotech-xbi.html.
SPDR S&P Biotech Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech (NYSEARCA:XBI).
Receive News & Ratings for SPDR S&P Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech and related companies with MarketBeat.com's FREE daily email newsletter.